Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11β-HSD1: Novel therapeutic agents for the treatment of metabolic syndrome
Keywords: اگزادیاازول; Metabolic syndrome; 11β-Hydroxysteroid dehydrogenase type I; 11β-HSD1; 11β-HSD2; Glucocorticoids; Cortisone; Cortisol; Bicyclo[2.2.2]octyltriazole; Heterocycle; Oxadiazole; Imidazole; Triazole; Pharmacokinectics; Pharmacodynamic assay